New research from the CDC suggests that the recent steep increase in cases of acute hepatitis C virus infection is associated with increases in opioid injection.
By: Corinna Dan, RN, MPH, Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
Responding to hepatitis A outbreaks requires partnerships between health departments, health centers, homeless service providers, & substance abuse services.
By: Corinna Dan, RN, MPH, Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services and Richard Wolitski, Ph.D., Director, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
Two webinars featured individuals and experts from the 11 priority populations in the National Viral Hepatitis Action Plan sharing their perspectives.
By: Corinna Dan, RN, MPH, Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
Clinician Consultation Center provides hepatitis C patient management consultation services on HCV treatment and co-morbidities such as HIV or substance use.
By: Corinna Dan, RN, MPH, Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
On World AIDS Day, HHS’s Corinna Dan discusses progress in improving hepatitis C (HCV) screening, care, and treatment for people living with HIV/HCV coinfection.
By: Corinna Dan, RN, MPH, Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
HEPLISAV-B is the first new hepatitis B vaccine approved in the U.S. in more than 25 years, and is the only two-dose HBV vaccine approved for adults.
By: Corinna Dan, RN, MPH, Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
The guidance provides updated FDA recommendations regarding the overall development program and clinical trial designs to support improved hepatitis C treatments.
